Alexion Pharmaceuticals

Consistent improvement with eculizumab across muscle groups in myasthenia gravis

Published in Annals of Clinical and Translational Neurology

Objective To assess whether eculizumab, a terminal complement inhibitor, improves patient‐ and physician‐reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative myasthenia gravis scale, respectively) in patients with refractory anti‐acetylcholine receptor antibody‐positive generalized myasthe...